A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Running, not enrolling · Phase 2

Conditions studied: Acute Pyelonephritis, Complicated Urinary Tract Infection

In brief

The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).

Key facts

Study ID
NCT06672978
Run by
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
People needed
66
Starts
2025-06-03
Expected to finish
2027-07-01
Last updated by the study team
2026-06-03

Who can join

Age: 0 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.